Free Trial
NASDAQ:IBRX

ImmunityBio 11/8/2023 Earnings Report

ImmunityBio logo
$2.86 -0.15 (-4.98%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.89 +0.03 (+1.05%)
As of 07/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

ImmunityBio Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImmunityBio Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

ImmunityBio's Q2 2025 earnings is scheduled for Monday, August 11, 2025

Conference Call Resources

ImmunityBio Earnings Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX), a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

View ImmunityBio Profile

More Earnings Resources from MarketBeat